Bayer

Last updated January 31, 2026

432

Innovation Areas

13,147

Inventors

104

Collaborations

Hydroxyurea and vaccinia virus co-formulation: BayerRecent Research Landscape

Poor immunogenicity of viral proteins often leads to therapeutic failure in chronic infections. Precise control of the antigen-adjuvant complex stabilizes the formulation to elicit a robust immune response.

What technical problems is Bayer addressing in Hydroxyurea and vaccinia virus co-formulation?

Uncontrolled oncogenic kinase signaling

(25)evidences

Weak endogenous immune responses fail to clear pathological cells. Enhancing activation thresholds overcomes systemic immune evasion and tolerance.

Therapeutic resistance and non-responsiveness

(16)evidences

Insufficient drug exposure and off-target toxicity limit efficacy. Improving the ratio of therapeutic benefit to adverse effects enables higher dosing safety.

Insufficient antibody binding specificity

(15)evidences

Endogenous natriuretic peptides suffer from rapid proteolytic degradation and renal clearance. Extending their functional presence in systemic circulation enables sustained therapeutic efficacy.

Off target cytotoxic toxicity

(7)evidences

Premature release of potent cytotoxic agents in non-target tissues causes severe adverse effects. Restricting activation to specific enzymatic environments prevents healthy cell damage.